Brief: Lyell Immunopharma To Acquire Immpact Bio And Prioritizes Its Pipeline To Focus On Next-Generation CAR T-cell Therapies
24/10/2024 23:16
Oct 24 (Reuters) - Lyell Immunopharma Inc LYEL.O :
* LYELL IMMUNOPHARMA TO ACQUIRE IMMPACT BIO AND PRIORITIZES
ITS
PIPELINE TO FOCUS ON NEXT-GENERATION CAR T-CELL THERAPIES
* LYELL IMMUNOPHARMA INC: IS DISCONTINUING DEVELOPMENT OF
LYL797,
LYL845 AND EARLIER-STAGE TIL PROGRAMS
Source text for Eikon: ID:nGNX8X7l0g
Further company coverage: LYEL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lyell Immunopharma
See all newsBrief: Lyell Immunopharma Says Additional Clinical Data And End-Of-Phase 1 FDA Meeting Expected In 2027
Lyell Immunopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary
Lyell Immunopharma, Inc. expected to post a loss of $2.08 a share - Earnings Preview
Brief: Lyell Immunopharma Q2 Operating Expenses USD 47.341 Million
Brief: Lyell Immunopharma Shows Updated Safety Data For Ronde-Cel In Patients With Large B-Cell Lymphoma